PATENT CLAIM ANALYSIS

Application Number: 16180316
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "469000"]

Abstract:
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Claim (Index 14):
The method of  claim 13  wherein the patient is totally blind.

Metadata:
- Claim Count in Document: 36.0
- Percentile: 98.0
- Lexical Diversity: 1.44828
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14374257', '13751011', '15378353', '15382526', '15822162']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8267948789645198
- 35 USC 102 Novelty (BERT): 0.6018641580203494
- Combined Prediction Score: 0.8043018068701028
- Mean Citation Score: 602.356314
- Max Citation Score: 616.0619
- Similarity Product: 442.4753190750361

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test